A patient with paresthesias, tremor, fatigue, cognitive dysfunction, and sensory disturbances arriving at a neurology clinic will often leave with an order for a multiple sclerosis (MS) workup. The reasoning is straightforward: the symptom list triggers the MS differential, and a prudent neurologist wants to exclude a treatable and progressive neurological disease before settling on less specific explanations. For patients with benzodiazepine-induced neurological dysfunction (BIND), this is usually the right clinical instinct to follow — MS can occur in patients who happen to have a benzodiazepine history, and its exclusion is genuinely useful. What often goes wrong is what happens after the MS workup returns negative, and what the rest of the differential should have included alongside MS from the beginning.
Why the MS Differential Gets Triggered
Several features of BIND present with neurological symptoms that a neurologist examining the patient for the first time could reasonably suspect for MS.
Paresthesias and dysesthesias. Tingling, numbness, burning sensations, and altered tactile perception can appear in various distributions. MS classically produces patchy, asymmetric sensory changes corresponding to demyelinating lesions; BIND produces more diffuse, bilateral sensory symptoms, but the distinction is not always clean at presentation.
Fatigue. Both conditions produce substantial fatigue that is disproportionate to activity.
Cognitive dysfunction. MS can produce slowed processing speed, attention difficulties, and executive dysfunction. BIND produces similar cognitive features. A neurologist evaluating the cognitive complaint alone may consider MS reasonably.
Visual symptoms. Blurred vision, floaters, and altered visual perception occur in both. Optic neuritis is a defining MS event; BIND does not produce optic neuritis but can produce visual symptoms that prompt an evaluation for it.
Tremor and motor symptoms. Tremor is common in BIND and can also appear in MS. Ataxia and coordination difficulties are less common in BIND than in MS but can occur.
Autonomic features. MS can involve urinary urgency, bowel changes, and sexual dysfunction; BIND frequently involves broader autonomic dysfunction. Overlap is real.
Balance and gait. Both conditions can affect balance.
What the MS Workup Typically Shows
The standard MS workup includes MRI of the brain and cervical spine with and without contrast, evaluation for cerebrospinal fluid (CSF) oligoclonal bands and IgG index, and often evoked potentials. Supportive laboratory evaluation typically includes vitamin B12, thyroid function, and other mimics.
In BIND, the findings are usually as follows.
MRI is typically unremarkable. There are no demyelinating lesions in the periventricular, juxtacortical, infratentorial, or spinal cord distributions that MS diagnostic criteria require. Brain parenchyma appears normal or shows age-appropriate changes.
CSF is typically negative for oligoclonal bands not present in serum, and the IgG index is not elevated. CSF cell counts and protein are unremarkable.
Evoked potentials, when performed, are usually normal or non-specific.
The workup essentially excludes MS.
What Should Be Part of the Differential Alongside MS
A neurologist evaluating the same symptom picture should ideally consider several additional diagnoses from the start, not only after MS has been excluded.
BIND itself. In a patient with long-term benzodiazepine exposure and recent taper or discontinuation, BIND is a specific diagnostic candidate that the 2023 Ritvo paper provides a framework for. The clinical features — time-locked to benzodiazepine changes, accompanied by autonomic and sensory hypersensitivity, and fluctuating in the waves-and-windows pattern — are recognizable.
Vitamin B12 deficiency. Low B12 produces peripheral neuropathy, paresthesias, ataxia, and cognitive symptoms. Serum B12 with methylmalonic acid and homocysteine for borderline values is appropriate.
Vitamin D deficiency. Severely low vitamin D has been associated with neurologic symptoms and is cheap to exclude.
Thyroid dysfunction. Both hyperthyroidism and hypothyroidism can produce cognitive, autonomic, and motor symptoms. TSH is standard.
Neuro-Lyme disease. In endemic regions or with compatible exposure history, Lyme serology is worth including in the workup, with awareness of the diagnostic limitations discussed separately.
Celiac disease. Celiac can produce peripheral neuropathy, ataxia, and cognitive symptoms, sometimes as the presenting features. Tissue transglutaminase IgA with total IgA is the screening combination.
Autoimmune autonomic neuropathy. In patients with prominent autonomic features, ganglionic acetylcholine receptor antibodies are worth considering.
Other demyelinating conditions. Neuromyelitis optica spectrum disorder (NMO) and MOG-antibody-associated disease produce MS-like pictures with distinct antibody markers. Aquaporin-4 and MOG antibodies are appropriate if the MRI shows compatible lesions that do not fit typical MS patterns.
Medication effects. Not only benzodiazepines but also fluoroquinolones, metronidazole, chemotherapy agents, statins in some patients, and other medications can produce neurological symptom pictures. Review of the full medication list is essential.
Functional neurological disorder. FND has specific rule-in criteria and should not be a diagnosis of exclusion after a normal workup. The clinician should test for FND signs specifically (Hoover’s sign, tremor entrainment, tubular vision fields) and apply the label only when they are present, not when everything else is negative.
Where the Diagnostic Error Usually Happens
The typical failure mode in this clinical scenario is a neurologist who completes an MS workup, finds it negative, and concludes “no neurological disease.” The symptoms are then attributed to anxiety, functional etiology, or somatization, and the patient is referred back to psychiatry or discharged from neurology follow-up.
This is an error for several reasons.
MS-negative does not mean neurological-disease-negative. The MS differential is narrow; many non-MS neurological conditions produce similar symptom pictures and require different tests to identify.
BIND is a neurological condition, not a psychiatric one, even though it lacks the structural imaging findings of classical neurology. A neurologist who does not consider pharmacologically-driven neurological dysfunction as part of the differential is working with an incomplete framework.
Defaulting to FND without rule-in criteria produces the misdiagnosis pattern discussed elsewhere on this site. FND exists as a positive diagnosis; it is not “everything else has been ruled out.”
What the Patient Can Ask For
For a patient headed into an MS workup in the context of a benzodiazepine history, several requests shift the evaluation toward a more useful outcome.
Ask that the benzodiazepine history and taper timeline be explicitly documented in the neurology note. A workup pursued in the context of acknowledged benzodiazepine exposure produces more useful subsequent discussion than a workup that implicitly treats the patient as free of relevant medication history.
Request that BIND be considered as one possibility alongside MS. Providing the Ritvo 2023 citation in advance can orient a neurologist unfamiliar with the framework.
Ask that the workup include B12, methylmalonic acid, homocysteine, vitamin D, TSH, celiac serology, and Lyme serology (where exposure is plausible) alongside the MRI and CSF. These are low-cost additions that broaden the differential meaningfully.
If the MS workup is negative, request that the neurologist document specifically which diagnoses are being considered next rather than defaulting to “non-neurological” or “functional.” A differential explicitly including BIND, mimic conditions, and specific alternative neurological diagnoses is more useful for future clinical care than a negative conclusion.
Ask for follow-up rather than discharge if BIND is being considered. BIND patients benefit from neurology follow-up even when the structural workup is negative; autonomic and sensory symptoms may require specific management, and the label of a recognized syndrome in the chart aids subsequent care.
What a Good Neurology Note Looks Like
For a BIND patient whose MS workup returned negative, a well-constructed neurology note reads something like this: structural MS workup is negative; the clinical picture is compatible with benzodiazepine-induced neurological dysfunction as described in Ritvo et al. 2023; alternative mimics (B12 deficiency, thyroid dysfunction, Lyme disease, celiac disease) have been evaluated and are not contributory; ongoing management will focus on the benzodiazepine taper and recovery with follow-up at regular intervals.
Compared to a note that says “no evidence of neurological disease; recommend psychiatric follow-up,” the useful version accomplishes several things: it acknowledges the syndrome by name, documents the negative workup in context, aligns future clinicians with the relevant framework, and preserves the clinical relationship for ongoing care.
The point of an MS workup in a BIND patient is to exclude MS. The workup accomplishes that efficiently when pursued appropriately. What matters equally is that the broader differential is considered from the start, so that a negative MS workup narrows the question rather than ending it.